Print
|
Close
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Active:
No
Cancer Type:
Lung Cancer
NCT ID:
NCT02200757
Trial Phases:
Phase II
Protocol IDs:
ALDOXORUBICIN-P2-SCLC-01 (primary)
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
ImmunityBio, Inc.
NCI Full Details:
http://clinicaltrials.gov/show/NCT02200757
Summary
The purpose of this study is to evaluate the efficacy and safety of aldoxorubicin
compared to topotecan in subjects with metastatic small cell lung cancer.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.